Skip to main content
Minerva Neurosciences, Inc. logo

Minerva Neurosciences, Inc. — Investor Relations & Filings

Ticker · NERV ISIN · US6033802058 LEI · 54930017PANCHC5LYH79 US Manufacturing
Open in API
Filings indexed 589 across all filing types
Latest filing 2017-05-31 Capital/Financing Update
Country US United States of America
Listing US NERV

About Minerva Neurosciences, Inc.

https://www.minervaneurosciences.com/

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company that focuses on the development and commercialization of product candidates for the treatment of central nervous system (CNS) diseases. The company's lead product candidate is roluperidone, which is being developed to treat the negative symptoms of schizophrenia. Minerva Neurosciences leverages its expertise in clinical development to design innovative trials with clinical endpoints aimed at demonstrating direct patient benefit.

Recent filings

Filing Released Lang Actions
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes a material definitive agreement, specifically a term sheet amendment between Minerva Neurosciences and Johnson & Johnson regarding a co-development and license agreement, as well as a stock repurchase agreement. There is no detailed financial data or comprehensive financial statements included, but rather an announcement of a significant contractual and capital structure update. This fits the category of Capital/Financing Update (CAP), as it involves financing terms, payments, and stock repurchase agreements. The document length is over 6,000 characters and contains substantive information about the agreements, not just a brief announcement or a certification. Therefore, the appropriate classification is CAP with high confidence.
2017-05-31 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K current report filed with the SEC, dated May 15, 2017. It includes references to press releases about the company's FDA meeting and Phase 3 development strategy, as well as an investor presentation attached as exhibits. The text does not contain actual financial statements or detailed financial analysis but rather announces events and provides links to press releases and a presentation. The document length is 3581 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, such a document that announces events and includes press releases and presentations is best classified as a Regulatory Filing (RNS), since it does not fit into other specific categories like Earnings Release or Investor Presentation (the presentation is attached but the document itself is the 8-K filing).
2017-05-15 English
FORM 10-Q
Interim / Quarterly Report Q1 2017
2017-05-04 English
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A Proxy Statement filed with the SEC, specifically labeled as "Definitive Additional Materials" related to the Annual Meeting of Minerva Neurosciences, Inc. It includes voting items such as election of directors and ratification of the independent auditor. The document is a solicitation of shareholder votes and provides information to shareholders to assist in voting decisions. It is not the proxy statement itself but additional materials related to it. This fits the definition of Proxy Solicitation & Information Statement (PSI). The document length is about 5,421 characters, which is consistent with a proxy solicitation document rather than a full annual report or other filings. Therefore, the correct classification is PSI with high confidence.
2017-04-18 English
DEF 14A
Proxy Solicitation & Information Statement
2017-04-18 English
FORM 4 SUBMISSION
Director's Dealing
2017-03-21 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.